Gene-editing technique to treat lung cancer is due to be tested in people in August
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique.
A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. The clinical trial received ethical approval from the hospital’s review board on July 6.
“It’s an exciting step forward,” says Carl June, a clinical researcher in immunotherapy at the University of Pennsylvania in Philadelphia.
There have been a number of human clinical trials using an alternative gene-editing technique, including one led by June, that have helped patients combat HIV. June is also a scientific adviser on a planned US trial that would also use CRISPR–Cas9-modified cells for the treatment of cancer.
Last month, an advisory panel of the US National Institutes of Health (NIH) approved that project. But the trial also requires a green light from the US Food and Drug Administration (FDA) and a university review board. The US researchers have said they could start their clinical trial by the end of this year.
Ineffective chemo
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed. “Treatment options are very limited,” says Lu. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”
Learn more: Chinese Scientists to Pioneer First Human CRISPR Trial
The Latest on: CRISPR
[google_news title=”” keyword=”CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR
- Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higheron May 11, 2024 at 5:42 am
CRISPR Therapeutics AG ( NASDAQ:CRSP) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The revenue forecast for this ...
- CRISPR edits fail to cure HIV patients in early teston May 10, 2024 at 10:13 am
Excision BioTherapeutics reported Friday that an early trial failed to cure HIV patients, but the company plans to try again with a more efficient editing treatment.
- CRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income Forecaston May 10, 2024 at 9:42 am
On May 8, 2024, CRISPR Therapeutics AG ( NASDAQ:CRSP) disclosed its first quarter financial results for 2024, revealing insights into its operational achievements and financial health. The company's ...
- Team develops efficient host-vector system for a model archaeon by solving CRISPR-based host-plasmid conflicton May 10, 2024 at 8:25 am
A research group has constructed versatile genetic tools for Saccharolobus islandicus REY15A, one of the very few archaeal models for archaea biology and CRISPR biology research.
- Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potentialon May 10, 2024 at 12:53 am
The forward-looking perspective suggests significant potential catalysts in the second half of the year, particularly regarding their leading CRISPR gene editing candidate, reni-cel. With the stock ...
- Buy Rating Affirmed for Crispr Therapeutics AG on Strong Pipeline and Financial Healthon May 9, 2024 at 10:25 pm
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating yesterday. Mani Foroohar has ...
- CRISPR-based gene editing treatment shows promise for rare eye disorderon May 9, 2024 at 8:08 am
Researchers at Oregon Health & Science University used an experimental CRISPR-based gene editing treatment in participants with a rare eye disorder that causes low vision and blindness. The results ...
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergon May 9, 2024 at 6:32 am
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- CRISPR gene editing trial treats inherited blindnesson May 9, 2024 at 1:24 am
Scientistse have restored vision and hearing in people born with congenital blindness or deafness in two seperate gene therapy trials A British toddler born deaf has become the first person to have ...
- Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindnesson May 8, 2024 at 9:28 am
A newer technology makes use of gene editing with the injection of EDIT-101. It is based on the use of clustered regularly interspaced short palindromic repeats (CRISPR) coupled with the ...
via Bing News